Osiris Therapeutics’s Buy Rating Reiterated at Piper Jaffray (OSIR)

Piper Jaffray restated their buy rating on shares of Osiris Therapeutics (NASDAQ:OSIR) in a research notereleased on Thursday morning, Market Beat reports. Piper Jaffray currently has a $28.00 price objective on the stock.

A number of other equities research analysts have also commented on the stock. Zacks Investment Research downgraded shares of Osiris Therapeutics from a hold rating to a sell rating in a research report on Monday, October 26th. Brean Capital upped their target priceon shares of Osiris Therapeutics from $19.00 to $25.00 and gave the stock a buy rating in a research report on Thursday, August 6th.

Shares of Osiris Therapeutics (NASDAQ:OSIR) opened at 10.20 on Thursday. Osiris Therapeutics has a 12-month low of $9.80 and a 12-month high of $23.67. The firm has a market capitalization of $351.41 million and a PE ratio of 242.86. The firm has a 50-day moving average of $15.69 and a 200-day moving average of $18.17.

Related Articles

Back to top button